The Roden Lab has a strong tradition of translating research
from the bedside to the bench and back again.
The overarching theme of our research is how genomic variation affects variability in disease susceptibility and response to drug treatment.
Our focus at the bench is on abnormalities of cardiac rhythm, and individual projects incorporate the expertise of the laboratory in mining electronic health records (EHRs) and in basic electrophysiologic methods, including the use of emerging medium and high-throughput approaches for functional genomics.
Principal Investigator Dr. Dan Roden is a leading researcher in pharmacogenomics and personalized medicine. In addition to the active projects listed below, he directed Vanderbilt’s site in the NIH’s Pharmacogenetics Research Network (PGRN) and the American Heart Association’s Strategically Focused Atrial Fibrillation Research Network (AF-SFRN).